A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus

Freeman, Jeffrey S.
December 2010
Mayo Clinic Proceedings;Dec2010 Supplement, Vol. 85, pS5
Academic Journal
Progressive deterioration of β-cell function is a hallmark of type 2 diabetes mellitus (DM). Together with increasing insulin resistance in peripheral tissues (in both the liver and the skeletal muscle), the inability of pancreatic insulin secretion to manage fasting and postprandial glucose levels results in hyperglycemia. Currently available oral antidiabetes agents improve glycemic parameters, but no single drug addresses the numerous pathophysiologic defects known to contribute to hyperglycemia in patients with type 2 DM. Dysregulation in the incretin system is another component of the pathophysiologic processes that lead to DM. Agents used to correct defects in the incretin system, such as glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, offer the potential to restore glucose-dependent insulin secretion and improve β-cell function. Glucagon-like peptide 1 receptor agonists also promote weight loss and provide beneficial effects on cardiovascular risk factors. A new approach that promotes the selection of pharmacotherapy for the treatment of patients with DM, with the goal of slowing or reversing the natural history of the disease, may be in order. Clinicians can select agents to address specific pathophysiologic defects to improve glycemia, with the hope of preventing the development of complications.


Related Articles

  • The predictive value of TNF-α and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Wu, Weihua; Wang, Mingli; Sun, Zhenjie; Wang, Xin; Miao, Jiajing; Zheng, Zhaohui // Acta Diabetologica;Feb2012, Vol. 49 Issue 1, p3 

    Some inflammation factors have been shown to accelerate type 2 diabetes macrovascular complication (T2DMC). The study investigates the variation of TNF-α and IL-6 levels during the progression of T2DMC to explore their predictive value in the incidence of T2DMC. All participants were divided...

  • Oxidative Stress and Heme Oxygenase-1 Regulated Human Mesenchymal Stem Cells Differentiation. Vanella, Luca; Sanford Jr., Christopher; Dong Hyun Kim; Abraham, Nader G.; Ebraheim, Nabil // International Journal of Hypertension;2012, p1 

    This paper describes the effect of increased expression of HO-1 protein and increased levels of HO activity on differentiation of bone-marrow-derived human MSCs. MSCs are multipotent cells that proliferate and differentiate into many different cell types including adipocytes and osteoblasts. HO,...

  • The Irrefutable Importance of Glycemic Control. Ousman, Yasser; Sharma, Meeta // Clinical Diabetes;Spring2001, Vol. 19 Issue 2, p71 

    Details findings of a prospective observational study designed to determine the relationship between exposure to glycemia over time and the risk of macrovascular and microvascular complications in patients with type 2 diabetes. Primary predefined aggregate clinical outcomes; Incidence of...

  • Tight glycemic control may not be best for all patients with diabetes?  // Endocrine Today;May2009, Vol. 7 Issue 7, p18 

    The article discusses research by Victor M. Montori and Mercè Fernández-Balsells which suggested that tight glycemic control may not reduce the risk for diabetes complications in patients with type 2 diabetes, published in a 2009 issue of "Annals of Internal Medicine."

  • Correction.  // Diabetes Care;Apr2012, Vol. 35 Issue 4, p939 

    A correction to the article "Effect of 3-Month Yoga on Oxidative Stress in Type 2 Diabetes With or Without Complications: A Controlled Clinical Trial," that appeared in the 2011 issue of "Diabetes Care" is presented.

  • Experts call for early, integrated approach to avoid type 2 diabetes complications.  // Endocrine Today;Jun2010 Supplement, Vol. 8, p25 

    The article highlights the findings of a survey on the views of physicians on the need for increased patient understanding of and early, integrated approach to type 2 diabetes complications.

  • Acute Glucose Infusion-Induced Insulin Resistance Occurs Independent of Defects in Insulin Signaling in Skeletal Muscle. Hoy, Andrew J.; Bruce, Clinton R.; Cederberg, Anna; Turner, Nigel; James, David E.; Cooney, Gregory J.; Kraegen, Edward W. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA341 

    Hyperglycemia is a defining feature of type 1 and 2 diabetes, and contributes directly to the development of the long term complications of diabetes. Hyperglycemia also causes insulin resistance, and we have recently demonstrated that hyperglycemia generated by glucose infusion results, in...

  • Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Miyashita, Yumi; Nishimura, Rimei; Nemoto, Masami; Matsudaira, Toru; Kurata, Hideaki; Yokota, Tamotsu; Yokota, Kuninobu; Tojo, Katsuyoshi; Utsunomiya, Kazunori; Tajima, Naoko // Cardiovascular Diabetology;2008, Vol. 7, p1 

    Background: The large clinical trials proved that Basal-Bolus (BB) insulin therapy was effective in the prevention of diabetic complications and their progression. However, BB therapy needs multiple insulin injections per a day. In this regard, a biphasic insulin analogue needs only twice-daily...

  • Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Litwinoff, EMS; Hurtado del Pozo, C; Ramasamy, R; Schmidt, AM // Clinical Pharmacology & Therapeutics;Aug2015, Vol. 98 Issue 2, p135 

    Types 1 and 2 diabetes are on the rise worldwide. Although the treatment of hyperglycemia has benefited from recent advances, aggressive efforts to maintain euglycemia may be fraught with risk, especially in older subjects or in subjects vulnerable to hypoglycemic unawareness. Hence, strategies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics